Legend Biotech Signals 2026 Profitability Push and CARVYKTI Expansion in Updated J.P. Morgan Presentation
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Legend Biotech ( (LEGN) ) has issued an update.
On January 14, 2026, Legend Biotech updated its corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its rapid revenue growth, improving operating margins, and an expected inflection to company-wide operating profit in 2026. The presentation underscored CARVYKTI’s strengthening commercial position—with more than 10,000 patients treated by late 2025, manufacturing capacity expanded across multiple global sites, and a 97% manufacturing success rate—as well as the strategic importance of its 50/50 global profit-sharing partnership with Johnson & Johnson in multiple myeloma, positioning the company as a leading player in cell therapy as it focuses on maximizing CARVYKTI’s market leadership, advancing pipeline innovation, and driving profitability.
The most recent analyst rating on (LEGN) stock is a Buy with a $66.00 price target. To see the full list of analyst forecasts on Legend Biotech stock, see the LEGN Stock Forecast page.
Spark’s Take on LEGN Stock
According to Spark, TipRanks’ AI Analyst, LEGN is a Neutral.
Legend Biotech’s strong revenue growth and strategic advancements in CARVYKTI are overshadowed by significant profitability and cash flow challenges. The technical indicators suggest bearish momentum, and the valuation metrics reflect ongoing financial struggles. While the earnings call provides a positive outlook, the company’s current financial health remains a concern.
To see Spark’s full report on LEGN stock, click here.
More about Legend Biotech
Legend Biotech Corporation is a global cell therapy company focused on developing and commercializing innovative treatments for cancer, particularly multiple myeloma. Its lead product, the CAR-T therapy CARVYKTI (ciltacabtagene autoleucel), is partnered with Johnson & Johnson and has become a top-selling CAR-T therapy, supported by a global manufacturing network, expansion into multiple markets, and a growing pipeline of cell therapy programs. The company operates major R&D facilities in the United States, employs more than 2,900 people worldwide, and is targeting profitability as its commercial operations scale.
Average Trading Volume: 1,992,502
Technical Sentiment Signal: Sell
Current Market Cap: $4.38B
See more insights into LEGN stock on TipRanks’ Stock Analysis page.
